On the regulatory approval pathway of biosimilar products

10.3390/ph5040353

Saved in:

Bibliographic Details
Main Authors:	Wang, J, Chow, S.-C
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Review
Published:	2020
Subjects:	biological product bioequivalence biological activity Canada clinical evaluation drug approval drug efficacy drug manufacture drug purity drug quality drug research drug safety drug stability European Medicines Agency European Union food and drug administration government regulation Japan Korea medical society organization pharmacodynamics pharmacokinetics physical chemistry political participation practice guideline review United States world health organization
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180841
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-180841
record_format	dspace
spelling	sg-nus-scholar.10635-1808412024-11-08T22:59:40Z On the regulatory approval pathway of biosimilar products Wang, J Chow, S.-C DUKE-NUS MEDICAL SCHOOL biological product bioequivalence biological activity Canada clinical evaluation drug approval drug efficacy drug manufacture drug purity drug quality drug research drug safety drug stability European Medicines Agency European Union food and drug administration government regulation Japan Korea medical society organization pharmacodynamics pharmacokinetics physical chemistry political participation practice guideline review United States world health organization 10.3390/ph5040353 Pharmaceuticals 5 4 353-368 2020-10-27T04:55:45Z 2020-10-27T04:55:45Z 2012 Review Wang, J, Chow, S.-C (2012). On the regulatory approval pathway of biosimilar products. Pharmaceuticals 5 (4) : 353-368. ScholarBank@NUS Repository. https://doi.org/10.3390/ph5040353 1424-8247 https://scholarbank.nus.edu.sg/handle/10635/180841 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	biological product bioequivalence biological activity Canada clinical evaluation drug approval drug efficacy drug manufacture drug purity drug quality drug research drug safety drug stability European Medicines Agency European Union food and drug administration government regulation Japan Korea medical society organization pharmacodynamics pharmacokinetics physical chemistry political participation practice guideline review United States world health organization
spellingShingle	biological product bioequivalence biological activity Canada clinical evaluation drug approval drug efficacy drug manufacture drug purity drug quality drug research drug safety drug stability European Medicines Agency European Union food and drug administration government regulation Japan Korea medical society organization pharmacodynamics pharmacokinetics physical chemistry political participation practice guideline review United States world health organization Wang, J Chow, S.-C On the regulatory approval pathway of biosimilar products
description	10.3390/ph5040353
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Wang, J Chow, S.-C
format	Review
author	Wang, J Chow, S.-C
author_sort	Wang, J
title	On the regulatory approval pathway of biosimilar products
title_short	On the regulatory approval pathway of biosimilar products
title_full	On the regulatory approval pathway of biosimilar products
title_fullStr	On the regulatory approval pathway of biosimilar products
title_full_unstemmed	On the regulatory approval pathway of biosimilar products
title_sort	on the regulatory approval pathway of biosimilar products
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/180841
_version_	1821214942014996480

On the regulatory approval pathway of biosimilar products

Similar Items